Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMI-150 for Breakthrough Cancer Pain
NCT00492388Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2007
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer pain comparing PMI-150 with Placebo (2 arms). Primary endpoint: Pain Intensity Difference at 60 minutes. Started Jun 2007; status: terminated.
02
Drugs
ketamine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00492388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492388.